Characteristics And Predictive Values Of Super-Responders In Alopecia Areata Under Tofacitinib Treatment: A Single-Center Retrospective Study
March 2025
in “
Clinical and Experimental Dermatology
”
Studysummary In this study, 37.5% of alopecia areata patients treated with tofacitinib were identified as super-responders, with significant predictors for this status being older age and no prior JAK inhibitor treatment, leading to faster and sustained hair regrowth.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on academic.oup.com →